high5md

The OncoAlert🚨 Lung faculty’s TOP 10 abstracts In Thoracic🫁 Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior #LungCancer experts across #NSCLC & #SCLC . A snapshot of what will shape LUNG oncology at #ASCO26 👇 🔹 HARMONI-6 — Ivonescimab + chemo vs tislelizumab + chemo in sqNSCLC (OS, Ph3) 🔹 LIBRETTO-432 — Adjuvant selpercatinib in RET+ NSCLC (EFS, Ph3) 🔹 WU-KONG28 — Sunvozertinib vs chemo in EGFR Ex20ins NSCLC (Ph3) 🔹 OPTITROP-LUNGO5 — Sac-TMT + pembrolizumab in PD-L1+ NSCLC (Ph3) 🔹 TRITON — Tremelimumab/durvalumab/chemo in STK11/KEAP1/KRAS-mut NSCLC 🔹 CROWN 7-year update — Lorlatinib vs crizotinib in ALK+ NSCLC 🔹 LORIN — Neoadjuvant lorlatinib in stage III ALK+ NSCLC 🔹 ACCELERET-LUNG — 1L pralsetinib in RET+ NSCLC 🔹 Silevertinib (BDTX-1535) — Non-classical EGFR-mut NSCLC 🔹 Concurrent CRT + durvalumab in ES-SCLC (Phase III) Leads @HHorinouchi @UOzkerim @WeOncologists Senior Faculty @GlopesMd @StephenVLiu @peters_solange @CharuAggarwalMD @MartinReck2 @christine_lovly Participating AF @DrMirallas Pinging faculty @bmassutis @UmbertoMalapel1 @jillfeldman4 @bensolomon1 @VanitaNoronha @DrSanjayPopat @DrJNaidoo @Latinamd @JulienMazieres @TerriConneran @BRicciutiMD

The OncoAlert🚨 GU faculty’s TOP 10 abstracts In GU Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior GU cancer experts across #ProstateCancer #KidneyCancer #BladderCancer . A snapshot of what will shape GU oncology at #ASCO26 👇 1️⃣ LBA5007 — TALAPRO-3 Talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC with HRR alterations 2️⃣ LBA1 — PROTEUS Perioperative apalutamide + ADT vs ADT in high-risk localized/locally advanced prostate cancer (final Phase 3) 3️⃣ 5001 — ENZAMET genomic analysis Decipher >0.85 to identify benefit from adding docetaxel to ADT + enzalutamide 4️⃣ LBA4511 — KEYNOTE-564 ctDNA ctDNA dynamics in RCC treated with adjuvant pembrolizumab vs placebo 5️⃣ 4502 — RAMPART Durvalumab vs active monitoring after resection in RCC (Phase 3 RCT) 6️⃣ 4500 — RADICAL (A031801) Radium-223 + cabozantinib in RCC with bone metastases 7️⃣ 4507 — EV-302 long-term follow-up Enfortumab vedotin + pembrolizumab vs chemotherapy in 1L LA/mUC 8️⃣ 4513 — AMBASSADOR (A031501) HRQoL with adjuvant pembrolizumab vs observation in high-risk MIBC 9️⃣ 4503 — SAKK 06/19 Perioperative intravesical rBCG + chemo-IO strategy in MIBC (primary analysis) 🔟 4510 — KEYNOTE-905 HRQoL with perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible MIBC Leads @nataliagandur @scocmem @AmandaNizamMD @WeOncologists Senior Faculty @montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @Silke_Gillessen @tompowles1 @AndreaNecchi @cdanicas @AOmlin Pinging @crisbergerot @HHammersMD @ravikanesvaran @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @brian_rini

🚨 The OncoAlert #BreastCancer faculty’s TOP 10 abstracts for #ASCO26 — selected by our leads and finalized through a Delphi voting process with senior breast cancer experts. 1️⃣ 500 — OPTIMA Test-directed chemotherapy in high-risk ER+/HER2- early BC 2️⃣ LBA1006 — PERSEVERA BC Giredestrant + palbociclib vs letrozole + palbociclib in 1L ER+/HER2- LA/MBC 3️⃣ 507 — KEYNOTE-522 final analysis Perioperative pembrolizumab in high-risk early TNBC 4️⃣ LBA1007 — SERENA-6 1L camizestrant for emergent ESR1 mutations — final PFS2 5️⃣ 502 — LIDERA BC Giredestrant in ER+/HER2- early BC by menopausal status 6️⃣ LBA1000 — ASCENT-04 SG + pembrolizumab vs chemo + pembrolizumab in 1L PD-L1+ mTNBC 7️⃣ 501 — NATALEE biomarker analysis Baseline gene expression and adjuvant ribociclib benefit 8️⃣ LBA503 — SENOMAC Omission of axillary dissection: OS + arm morbidity 9️⃣ 1001 — ASCENT-03 SG vs chemotherapy in 1L mTNBC — PFS2 🔟 LBA1003 Izalontamab brengitecan vs physician’s choice chemo in metastatic TNBC Leads🚨 @ElisaAgostinett @to_be_elizabeth @WeOncologists Senior Faculty @ErikaHamilton9 @E_de_Azambuja @matteolambe @DrSGraff @hoperugo @BianchiniGP Dr. Bidard @Icro_Meattini Participating AF @Lucarecco @GaiaGriguolo Ping Faculty @aftimosp @double_whammied @stage4kelly @coffeemommy @itsnot_pink @maryam_lustberg @IBCResearch @kevinpunie @nicolobattisti @raalbany @teamoncology @stolaney1 @LoiSher @SirohiBhawna @chemobrainfog @jamecancerdoc @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @paspears88 @MammaMiaMagazin @itrisabel

Our collaborators at high5Oncology have brought together leading international experts in GU cancer, and their insights are now available online—follow for the latest news and expert analysis from Berlin! buff.ly/3NuVFAr @amerseburger @EfstathiouEleni @weoncologists @nachoduranm @GoebellJ @HHammersMD @IvanyiPhilipp @montypal @brian_rini @OncoBellmunt @scserendipity1 @GoebellJ @PGrivasMDPhD @IvanyiPhilipp @y_loriot @tompowles1 @bjartell @scserendipity1 @EfstathiouEleni @grimm_mo @amerseburger @declangmurphy @nealshore @OncoAlert

Our Collaborators at @high5md have gathered top international experts in Lung Cancer and have commenced their full reports from ESMO25. Visit them for the Top News out of Berlin! WATCH HERE: buff.ly/3NuVFAr

Dear Colleagues at #ESMO25 Our Collaborators at High5Oncology are here in Berlin capturing some great meeting content and special interviews from some of the leading experts in the field. Visit them at👉 buff.ly/EjymG69

Check out these Great video links from our Collaborators at @high5md straight from #ASCO25 *GU oncology* CREST buff.ly/7vmusUL AMPLITUDE & TALAPRO buff.ly/NuVHdIN ARCHES, ARANOTE & IRONMAN buff.ly/NuVHdIN *Breast Cancer* VERITAC-2 buff.ly/Ik2Ga9s INAVO-120 buff.ly/gq6dcGp ASCENT04 buff.ly/i7es7ZN DESTINY Breast 09 buff.ly/cEdzgCj *Lung Cancer* DELLPHI 304 buff.ly/IJiumuu IMForte buff.ly/V9QQ3sm KRYSTAL7 buff.ly/i6FUMj2 CheckMate 816 buff.ly/RK52Mjw

EMBER3 Presented at #SABCS24 and out on @NEJM Report with Peter Fasching ( @high5md ) buff.ly/3OZdxXF Imlunestrant is a novel oral medication that targets and degrades estrogen receptors (ER), even in breast cancers resistant to traditional hormone therapies due to ER mutations. A phase 3 clinical trial evaluated imlunestrant's efficacy in patients with advanced ER-positive, HER2-negative breast cancer. The study found that imlunestrant significantly prolonged progression-free survival in patients with ESR1 mutations compared to standard endocrine therapy. However, it did not demonstrate a significant benefit in the overall patient population. The combination of imlunestrant with abemaciclib, a CDK4/6 inhibitor, significantly improved progression-free survival compared to imlunestrant alone, regardless of ESR1 mutation status. While imlunestrant offers a promising new treatment option for patients with ER-positive breast cancer, particularly those with ESR1 mutations, further research is needed to optimize its use and identify potential combination therapies. Take Home Imlunestrant, a novel oral medication, significantly improved progression-free survival in patients with ER-positive, HER2-negative advanced breast cancer, especially those with ESR1 mutations.

The PADMA trial presented at #SABCS24 Report with Alessandra Gennari @ALEDIGNUS12 ( @high5md ) high5oncology.tv/meeting-cov… Demonstrated that palbociclib plus endocrine therapy significantly improves time to treatment failure and progression-free survival compared to chemotherapy in high-risk HR+/HER2- metastatic breast cancer, supporting its use as the standard first-line treatment.

Coming Soon @high5md & @OncoAlert 🚨 Straight out of #SABCS24 @Prof_Nadia_H @hoperugo @BarbaraPistill2 and many more........Stay Tuned #BreastCancer

Dear Colleagues at #SABCS24 Join our collaborators at @high5md for the latest #BreastCancer updates directly from San Antonio Visit them at: buff.ly/49Dc42Q Featuring insights from some of the world’s leading international breast cancer experts Experts include @KalinskyKevin @matteolambe @jhaveri_komal @hoperugo @stolaney1 @Prof_Nadia_H @Icro_Meattini and many more buff.ly/49Dc42Q

Follow Our Collaborators at @high5md to get updated on the great science out of #ESMO24 by some of the TOP #BreastCancer Experts in the world 🌐 Find them Here: high5oncology.tv/meeting-cov…

A warm invite from our Collaborators at @high5md to join us for excellent discussions around all of the #ProstateCancer #BladderCancer & #KidneyCancer data Presented at #ESMO24 with a TOP Group of International GU experts. high5oncology.tv/meeting-cov… @OncoBellmunt @bjartell @scserendipity1 @nachoduranm @EfstathiouEleni @GoebellJ @grimm_mo @PGrivasMDPhD @y_loriot @amerseburger @weoncologists @tompowles1

A warm invite from our Collaborators at @high5md to join us for excellent discussions around all of the #BreastCancer data Presented at #ESMO24 with a TOP Group of International Breast #Cancer experts high5oncology.tv/meeting-cov… @curijoey @volkmar_mueller @ALEDIGNUS12 @DLueftner @BarbaraPistill2 @FlaggschiffFilm @Prof_Nadia_H @stolaney1

A warm invite from @high5md to tune into high5Oncology TV for the TOP News out of #ESMO24 by great International experts Tune in here: high5oncology.tv/meeting-cov…

Dear Colleagues at #ESMO24 @high5md gives you expert reports on key oncology conferences, offering concise updates or in-depth discussions on practice-changing findings, new studies, and groundbreaking data. FREE DIVE IN, HERE: high5oncology.tv/meeting-cov…

Our Collaborators at @high5md are Here at #ESMO24 Bringing you Expert highlights and commentaries from all of the GREAT Science out of Barcelona by an amazing faculty Link: high5oncology.tv/meeting-cov…

To our dear amigos, the @Uromigos 🤠 We proudly present our official entry for the Golden Ticket to attend Uromigos Live & Unplugged in Nashville this September 🎫 On behalf of the #OncoAlertAF 🚨GU Renegades, our Posse is: - Natalia “Quick Draw” Gandur @nataliagandur 🇦🇷 - Emre “6 Shooter” Yekeduz @yekeduz_emre 🇺🇸 - Barbara “Blades” Melao @bavilima 🇧🇷 Wanted for the fastest posts this side of the Mississippi! Pinging our GU Faculty @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @cdanicas @DrYukselUrun @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @yekeduz_emre @DrYukselUrun